These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 14754693)

  • 21. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response.
    Bump RC; Norton PA; Zinner NR; Yalcin I;
    Obstet Gynecol; 2003 Jul; 102(1):76-83. PubMed ID: 12850610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Raloxifene: results from the MORE study.
    Agnusdei D; Iori N
    J Musculoskelet Neuronal Interact; 2000 Dec; 1(2):127-32. PubMed ID: 15758505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
    Schaefers M; Muysers C; Alexandersen P; Christiansen C
    Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open retropubic colposuspension for urinary incontinence in women: a short version Cochrane review.
    Lapitan MC; Cody JD; Grant A
    Neurourol Urodyn; 2009; 28(6):472-80. PubMed ID: 19591206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
    [No Abstract]   [Full Text] [Related]  

  • 28. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
    Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incontinence severity and major depression in incontinent women.
    Melville JL; Delaney K; Newton K; Katon W
    Obstet Gynecol; 2005 Sep; 106(3):585-92. PubMed ID: 16135592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vaginal estriol administration in treatment of postmenopausal urinary incontinence].
    Schmidbauer CP
    Urologe A; 1992 Nov; 31(6):384-9. PubMed ID: 1462489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
    Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
    J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
    Green SA; Alon A; Ianus J; McNaughton KS; Tozzi CA; Reiss TF
    J Urol; 2006 Dec; 176(6 Pt 1):2535-40; discussion 2540. PubMed ID: 17085151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y; Wong M; Thiebaud D; Stock JL
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
    Adomaityte J; Farooq M; Qayyum R
    Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe depression determines quality of life in urinary incontinent women.
    Stach-Lempinen B; Hakala AL; Laippala P; Lehtinen K; Metsänoja R; Kujansuu E
    Neurourol Urodyn; 2003; 22(6):563-8. PubMed ID: 12951664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary incontinence in women: variation in prevalence estimates and risk factors.
    Minassian VA; Stewart WF; Wood GC
    Obstet Gynecol; 2008 Feb; 111(2 Pt 1):324-31. PubMed ID: 18238969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence of and potential risk factors for female urinary incontinence in Beijing, China.
    Zhu L; Lang J; Wang H; Han S; Huang J
    Menopause; 2008; 15(3):566-9. PubMed ID: 18467955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
    Ensrud K; Genazzani AR; Geiger MJ; McNabb M; Dowsett SA; Cox DA; Barrett-Connor E
    Am J Cardiol; 2006 Feb; 97(4):520-7. PubMed ID: 16461049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.